Granted Patent
B2
US 12,533,332 · App. 18/509,114 · Granted Jan 27, 2026
Compositions and methods for treating chronic inflammation and inflammatory diseases
Inventors:
Robin M. Bannister (Saffron Walden, GB); John Brew (St. Albans, GB); Wilson Caparros Wanderley (Aylesbury, GB); Gregory A. Stoloff (London, GB); Suzanne J. Dilly (Oxfordshire, GB); Gemma Szucs (Oxfordshire, GB); Olga Pleguezuelos Mateo (Bicester, GB)
Assignee:
Infirst Healthcare Limited
A61K31/192A61K9/08A61K9/2013A61K31/196A61K31/60A61K47/10A61K47/14A61K47/34A61K47/44A61K31/19A61K31/215A61K31/216A61K31/22A61K31/40Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
Claims (27)
1 . A pharmaceutical composition comprising:
a) a pharmaceutically-acceptable form of a peroxisome proliferator-activated receptor gamma (PPARγ) agonist in a concentration of at least 10 mg/mL; and
b) at least 50% by weight of the composition of pharmaceutically-acceptable glycerolipids comprising monoglycerides, diglycerides, and triglycerides;
wherein the pharmaceutical composition is formulated to have a melting point temperature of about 30° C. or higher.
2 . The pharmaceutical composition according to claim 1 , wherein the concentration of the PPARγ agonist is at least 25 mg/mL.
3 . The pharmaceutical composition according to claim 2 , wherein the concentration of the PPARγ agonist is at least 50 mg/mL.
4 . The pharmaceutical composition according to claim 3 , wherein the concentration of the PPARγ agonist is about 100 mg/mL to about 1,000 mg/mL.
5 . The pharmaceutical composition according to claim 4 , wherein the concentration of the PPARγ agonist is about 100 mg/mL to about 500 mg/mL.
6 . The pharmaceutical composition according to claim 1 , wherein the PPARγ agonist is a pharmaceutically acceptable salt, solvate, or solvate of a salt thereof.
7 . The pharmaceutical composition according to claim 1 , wherein the PPARγ agonist is an ester thereof.
8 . The pharmaceutical composition according to claim 1 , wherein the PPARγ agonist comprises a cannabidiol, a delta(9)-tetrahydrocannabinol, or any combination thereof.
9 . The pharmaceutical composition according to claim 1 , wherein the amount of the pharmaceutically-acceptable glycerolipids is about 50% to about 95% by weight of the composition.
10 . The pharmaceutical composition according to claim 1 , wherein the amount of the pharmaceutically-acceptable glycerolipids is at least 65% by weight of the composition.
11 . The pharmaceutical composition according to claim 10 , wherein the amount of the pharmaceutically-acceptable glycerolipids is at least 75% by weight of the composition.
12 . The pharmaceutical composition according to claim 1 , wherein the amount of the triglycerides is at least 35% by weight of the composition.
13 . The pharmaceutical composition according to claim 12 , wherein the amount of the triglycerides is at least 45% by weight of the composition.
14 . The pharmaceutical composition according to claim 1 , wherein the amount of the monoglycerides is at least 10% by weight of the composition.
15 . The pharmaceutical composition according to claim 1 , further comprising a liquid PEG polymer.
16 . The pharmaceutical composition according to claim 15 , wherein the liquid PEG polymer is in an amount of less than about 10% by weight of the composition.
17 . The pharmaceutical composition according to claim 16 , wherein the liquid PEG polymer is in an amount of less than about 5% by weight of the composition.
18 . The pharmaceutical composition according to claim 17 , wherein the liquid PEG polymer is in an amount of about 1% by weight of the composition.
19 . The pharmaceutical composition according to claim 1 , comprising:
a) wherein the PPARγ agonist is a cannabidiol, a delta(9)-tetrahydrocannabinol, or any combination thereof, wherein the cannabidiol is present in an about of 100 mg/mL to about 750 mg/mL, and wherein the delta(9)-tetrahydrocannabinol is present in an amount of about 100 mg/mL to about 750 mg/mL; and
b) wherein the pharmaceutically-acceptable glycerolipids are present in an amount of at least 65% by weight of the composition.
20 . The pharmaceutical composition according to claim 1 ,
a) wherein the PPARγ agonist is a cannabidiol, the cannabidiol being present in an amount of about 100 mg/mL to about 500 mg/mL; and
b) wherein the pharmaceutically-acceptable glycerolipids are present in an amount of at least 65% by weight of the composition.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 3, 2023
From: BANNISTER, ROBIN M.; BREW, JOHN; CAPARROS WANDERLEY, WILSON; DILLY, SUZANNE JANE; SZUCS, GEMMA; PLEGUEZUELOS MATEO, OLGA; STOLOFF, GREGORY M.
To: BIOCOPEA LIMITED
Reel/Frame 065741/0299 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 3, 2023
From: BIOCOPEA LIMITED
To: IMMUNOCOPEA LIMITED
Reel/Frame 065741/0310 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 3, 2023
From: IMMUNOCOPEA LIMITED
To: INFIRST HEALTHCARE LIMITED
Reel/Frame 065741/0322 →
Priority Claims (5)
GB 1018289
· Oct 29, 2010
· national
GB 1101937
· Feb 4, 2011
· national
GB 1113728
· Aug 10, 2011
· national
GB 1113729
· Aug 10, 2011
· national
GB 1113730
· Aug 10, 2011
· national
Continuity (10)
Continuation In Part
PCTGB2011052115
· Oct 31, 2011
References Cited (256)
US 3228831A
· Nicholson et al.
· 1966
[cited by applicant]
US 3800038A
· Rudel
· 1974
[cited by applicant]
US 4571400A
· Arnold
· 1986
[cited by applicant]
US 4684666A
· Haas
· 1987
[cited by applicant]
US 4918103A
· Park et al.
· 1990
[cited by applicant]
US 5011852A
· Park et al.
· 1991
[cited by applicant]
US 5059626A
· Park et al.
· 1991
[cited by applicant]
US 5154930A
· Popescu
· 1992
[cited by applicant]
US 5210099A
· Mody et al.
· 1993
[cited by applicant]
US 5256699A
· Murphy et al.
· 1993
[cited by applicant]
US 5445822A
· Bracco
· 1995
[cited by applicant]
US 5527545A
· Santus et al.
· 1996
[cited by applicant]
US 5552160A
· Liversidge et al.
· 1996
[cited by applicant]
US 5645856A
· Lacy et al.
· 1997
[cited by applicant]
US 5955451A
· Lichtenberger et al.
· 1999
[cited by applicant]
US 6214386B1
· Santus
· 2001
[cited by applicant]
US 6264981B1
· Zhang
· 2001
[cited by applicant]
US 6267985B1
· Chen et al.
· 2001
[cited by applicant]
US 6294192B1
· Patel et al.
· 2001
[cited by applicant]
US 6319513B1
· Dobrozsi
· 2001
[cited by applicant]
US 6383471B1
· Chen et al.
· 2002
[cited by applicant]
US 6451339B2
· Patel et al.
· 2002
[cited by applicant]
US 6455067B1
· Woo et al.
· 2002
[cited by applicant]
US 6923988B2
· Patel et al.
· 2005
[cited by applicant]
US 7473432B2
· Cevc et al.
· 2009
[cited by applicant]
US 8663692B1
· Muller et al.
· 2014
[cited by applicant]
US 8895536B2
· Bannister
· 2014
[cited by examiner]
US 8895537B2
· Bannister
· 2014
[cited by examiner]
US 9265724B2
· Murty
· 2016
[cited by examiner]
US 9265742B2
· Bannister et al.
· 2016
[cited by applicant]
US 9271950B2
· Bannister et al.
· 2016
[cited by applicant]
US 9308213B2
· Bannister et al.
· 2016
[cited by applicant]
US 9326958B2
· Bannister et al.
· 2016
[cited by applicant]
US 9381180B2
· Bannister
· 2016
[cited by examiner]
US 9427422B2
· Bannister et al.
· 2016
[cited by applicant]
US 9504664B2
· Bannister et al.
· 2016
[cited by applicant]
US 9693980B2
· Bannister et al.
· 2017
[cited by applicant]
US 9737500B2
· Bannister et al.
· 2017
[cited by applicant]
US 9744132B2
· Bannister et al.
· 2017
[cited by applicant]
US 9750810B2
· Bannister et al.
· 2017
[cited by applicant]
US 9775820B2
· Bannister et al.
· 2017
[cited by applicant]
US 9789075B2
· Bannister et al.
· 2017
[cited by applicant]
US 9795577B2
· Bannister et al.
· 2017
[cited by applicant]
US 9820952B2
· Bannister et al.
· 2017
[cited by applicant]
US 9827215B2
· Bannister et al.
· 2017
[cited by applicant]
US 20010005726A1
· Woo et al.
· 2001
[cited by applicant]
US 20010006650A1
· Burnside et al.
· 2001
[cited by applicant]
US 20030008003A1
· Jamali
· 2003
[cited by applicant]
US 20030170279A1
· Lambert et al.
· 2003
[cited by applicant]
US 20030232097A1
· Radhakrishnan et al.
· 2003
[cited by applicant]
US 20050152968A1
· Brophy et al.
· 2005
[cited by applicant]
US 20060034937A1
· Patel
· 2006
[cited by applicant]
US 20060062810A1
· Woo et al.
· 2006
[cited by applicant]
US 20060078616A1
· Georgewill et al.
· 2006
[cited by applicant]
US 20070015834A1
· Flashner-Barak et al.
· 2007
[cited by applicant]
US 20070036831A1
· Baker
· 2007
[cited by applicant]
US 20070048284A1
· Donahue et al.
· 2007
[cited by applicant]
US 20070048384A1
· Rosenberg et al.
· 2007
[cited by applicant]
US 20070092559A1
· Yuan
· 2007
[cited by applicant]
US 20070104741A1
· Murty et al.
· 2007
[cited by applicant]
US 20070105912A1
· Holm et al.
· 2007
[cited by applicant]
US 20080153894A1
· Britten et al.
· 2008
[cited by applicant]
US 20080154210A1
· Jordan et al.
· 2008
[cited by applicant]
US 20090130029A1
· Tamarkin et al.
· 2009
[cited by applicant]
US 20090304782A1
· De Blas et al.
· 2009
[cited by applicant]
US 20100125060A1
· Razzak et al.
· 2010
[cited by applicant]
US 20110142945A1
· Chen et al.
· 2011
[cited by applicant]
US 20130178448A1
· Bannister et al.
· 2013
[cited by applicant]
US 20170043016A1
· Bannister et al.
· 2017
[cited by applicant]
CN 1736369A
· 2006
[cited by applicant]
CN 101129335A
· 2008
[cited by applicant]
CN 102793628A
· 2012
[cited by applicant]
EP 306060A2
· 1989
[cited by applicant]
EP 0521344A2
· 1993
[cited by applicant]
EP 1923060A1
· 2008
[cited by applicant]
EP 1352638B1
· 2009
[cited by applicant]
FR 2810243A1
· 2001
[cited by applicant]
GB 2331458A
· 1999
[cited by applicant]
GB 2477590A
· 2011
[cited by applicant]
JP 6009381A
· 1992
[cited by applicant]
JP 2008143807A
· 2006
[cited by applicant]
JP 2009155282A
· 2009
[cited by applicant]
WO 1986000802A1
· 1986
[cited by applicant]
WO 1992009272A1
· 1992
[cited by applicant]
WO 1995011039A1
· 1995
[cited by applicant]
WO 1997003655A1
· 1997
[cited by applicant]
WO 1998000169A1
· 1998
[cited by applicant]
WO 1998025595A2
· 1998
[cited by applicant]
WO 1999006024A1
· 1999
[cited by applicant]
WO 1999021534A1
· 1999
[cited by applicant]
WO 2000027372A1
· 2000
[cited by applicant]
WO 2000057859A1
· 2000
[cited by applicant]
WO 2000067728A2
· 2000
[cited by applicant]
WO 2000076478A1
· 2000
[cited by applicant]
WO 2002085414A2
· 2002
[cited by applicant]
WO 2003013566A1
· 2003
[cited by applicant]
WO 2004082588A2
· 2004
[cited by applicant]
WO 2005009436A1
· 2005
[cited by applicant]
WO 2005079752A2
· 2005
[cited by applicant]
WO 2005087194A1
· 2005
[cited by applicant]
WO 2006037348A1
· 2006
[cited by applicant]
WO 2006057903A2
· 2006
[cited by applicant]
WO 2006096806A2
· 2006
[cited by applicant]
WO 2006099325A2
· 2006
[cited by applicant]
WO 2006115463A1
· 2006
[cited by applicant]
WO 2007138339A2
· 2007
[cited by applicant]
WO 2008002121A2
· 2008
[cited by applicant]
WO 2008070950A1
· 2008
[cited by applicant]
WO 2008120207A3
· 2008
[cited by applicant]
WO 2008134512A1
· 2008
[cited by applicant]
WO 2009033131A2
· 2009
[cited by applicant]
WO 2009047785A3
· 2009
[cited by applicant]
WO 2009067734A1
· 2009
[cited by applicant]
WO 2009069139A1
· 2009
[cited by applicant]
WO 2010059717A2
· 2010
[cited by applicant]
WO 2010087947A2
· 2010
[cited by applicant]
WO 2010097332A1
· 2010
[cited by applicant]
WO 2010097334A1
· 2010
[cited by applicant]
WO 2010103312A1
· 2010
[cited by applicant]
WO 2010125060A1
· 2010
[cited by applicant]
WO 2011095814A1
· 2011
[cited by applicant]
WO 2012056251A1
· 2012
[cited by applicant]
WO 2012104654A1
· 2012
[cited by applicant]
WO 2012104655A2
· 2012
[cited by applicant]
WO 2012127037A2
· 2012
[cited by applicant]
WO 2014108569A1
· 2014
[cited by applicant]
WO 2014108572A1
· 2014
[cited by applicant]
WO 2014108573A1
· 2014
[cited by applicant]
WO 2014108574A1
· 2014
[cited by applicant]
WO 2014117999A1
· 2014
[cited by applicant]
WO 2017025517A1
· 2017
[cited by applicant]
WIPO, PCT Form ISA210, International Search Report for International Patent Application Serial No. PCT/EP2014/050637, pp. 4 (May 22, 2014).
[cited by applicant]
WIPO, PCT Form ISA237, Written Opinion for International Patent Application Serial No. PCT/EP2014/050637, pp. 6 (May 22, 2014).
[cited by applicant]
WIPO, PCT Form IB373, International Preliminary Report on Patentability for International Patent Application Serial No. PCT/EP2014/050637, pp. 25 (Apr. 8, 2015).
[cited by applicant]
WIPO, PCT Form ISA210, International Search Report for International Patent Application Serial No. PCT/ EP2014/050638, pp. 4 (Apr. 3, 2014).
[cited by applicant]
WIPO, PCT Form ISA237, Written Opinion for International Patent Application Serial No. PCT/EP2014/050638, pp. 6 (Apr. 3, 2014).
[cited by applicant]
WIPO, PCT Form IB373, International Preliminary Report on Patentability for International Patent Application Serial No. PCT/EP2014/050638, pp. 7 (Jul. 14, 2015).
[cited by applicant]
WIPO, PCT Form ISA210, International Search Report for International Patent Application Serial No. PCT/ EP2016/068900, pp. 3 (Oct. 26, 2016).
[cited by applicant]
WIPO, PCT Form ISA237, Written Opinion for International Patent Application Serial No. PCT/EP2016/068900, pp. 6 (Oct. 26, 2016).
[cited by applicant]
WIPO, PCT Form IB373, International Preliminary Report on Patentability for International Patent Application Serial No. PCT/EP2016/068900, pp. 7 (Feb. 22, 2018).
[cited by applicant]
Zeberg-Mikkelsen, et al., Predicting the Melting Points and the Enthalpies of Fusion of Saturated Triglycerides by a Group Contribution Method, Fluid Phase Equilibria 162: 7-17 (1999).
[cited by applicant]
U.S. Appl. No. 17/378,744, filed Jul. 18, 2021, US 2021/0338617.
[cited by applicant]
U.S. Appl. No. 17/146,950, filed Jan. 12, 2021, US 2021/0137864, U.S. Pat. No. 11,065,218.
[cited by applicant]
U.S. Appl. No. 17/107,724, filed Nov. 30, 2020, US 2021/0077441, U.S. Pat. No. 11,660,276.
[cited by applicant]
U.S. Appl. No. 13/376,079, filed Feb. 6, 2012, US 2012-0128738, U.S. Pat. No. 8,703,158.
[cited by applicant]
U.S. Appl. No. 13/446,217, filed Apr. 13, 2012, US 2012-0270899.
[cited by applicant]
U.S. Appl. No. 13/576,758, filed Dec. 14, 2012, US 2013-0178448.
[cited by applicant]
U.S. Appl. No. 14/155,147, filed Jan. 14, 2014, US 2014-0128353, U.S. Pat. No. 10,695,431.
[cited by applicant]
U.S. Appl. No. 14/155,167, filed Jan. 14, 2014, US 2014-0162987, U.S. Pat. No. 10,695,432.
[cited by applicant]
U.S. Appl. No. 14/991,892, filed Jan. 8, 2016, US 2016-0120899.
[cited by applicant]
U.S. Appl. No. 15/144,798, filed May 2, 2016, US 2016-0271136.
[cited by applicant]
U.S. Appl. No. 15/144,800, filed May 2, 2016, US 2016-0271197.
[cited by applicant]
U.S. Appl. No. 15/289,083, filed Oct. 7, 2016, US 2017-0043016.
[cited by applicant]
U.S. Appl. No. 16/166,272, filed Oct. 22, 2018, US 2019-0070137, U.S. Pat. No. 10,596,132.
[cited by applicant]
U.S. Appl. No. 16/206,789, filed Nov. 30, 2018, US 2019-0091334, U.S. Pat. No. 10,653,778.
[cited by applicant]
U.S. Appl. No. 16/206,814, filed Nov. 30, 2018, US 2019-0091185, U.S. Pat. No. 10,588,878.
[cited by applicant]
U.S. Appl. No. 16/284,221, filed Feb. 25, 2019, US 2019-0183795, U.S. Pat. No. 10,835,490.
[cited by applicant]
U.S. Appl. No. 16/525,520, filed Jul. 29, 2019, US 2019-0350886, U.S. Pat. No. 10,857,114.
[cited by applicant]
U.S. Appl. No. 16/729,363, filed Dec. 28, 2019, US 2020-0129461.
[cited by applicant]
U.S. Appl. No. 16/818,668, filed Mar. 13, 2020, US 2020-0206170, U.S. Pat. No. 11,000,493.
[cited by applicant]
U.S. Appl. No. 16/882,667, filed May 25, 2020, US 2020-0316025, U.S. Pat. No. 11,224,659.
[cited by applicant]
U.S. Appl. No. 17/113,476, filed Dec. 7, 2020, US 2021-0085505, U.S. Pat. No. 11,730,709.
[cited by applicant]
U.S. Appl. No. 17/230,855, filed Apr. 14, 2021, US 2021-0228514, U.S. Pat. No. 11,844,773.
[cited by applicant]
U.S. Appl. No. 17/448,263, filed Sep. 21, 2021, US 2022-0040102, U.S. Pat. No. 11,992,555.
[cited by applicant]
U.S. Appl. No. 17/540,802, filed Dec. 2, 2021, US 2022-0096637, U.S. Pat. No. 11,826,428.
[cited by applicant]
U.S. Appl. No. 17/646,241, filed Dec. 28, 2021, US 2022-0118091, U.S. Pat. No. 11,918,654.
[cited by applicant]
U.S. Appl. No. 18/595,716, filed Mar. 5, 2024, US 2024-0207408.
[cited by applicant]
U.S. Appl. No. 18/641,775, filed Apr. 22, 2024, US 2024-0277613.
[cited by applicant]
BASF MONOMULS® 90-L 12, Personal Care BASF, Product Details, URL: http://www.personalcare.basf.com/ProductDetails?PRD=30527768, pp. 4 (downloaded May 4, 2015).
[cited by applicant]
Chung, et al., Oil Components Modulate Physical Characteristics and Function of the Natural Oil Emulsions as Drug or Gene Delivery System, J. Controlled Rel. 71: 339-350 (2001).
[cited by applicant]
Csizmazia, E., et al., Penetration Enhancer Effect of Sucrose Laurate and Transcutol on Ibuprofen, J. Drug Del. Sci. Tech. 21(5): (2011).
[cited by applicant]
Department of Health and Human Services, Attachment 3: Stability Background and Data Presentation, pp. 8 (downloaded Jan. 15, 2015).
[cited by applicant]
Elburg Global, Hydrogenated Coconut Oil, URL: http://www.elburgglobal.nl/fileadmin/brochures/PDS_Hydr._Coconut_oil.pdf, p. 1, (downloaded Aug. 4, 2010).
[cited by applicant]
Gattefosse, Maisine 35-1, Physicochemical Data Sheet (PCS), pp. 2 (last updated Nov. 28, 2013).
[cited by applicant]
Gattefosse, Range of Products, URL: https://www.gattefosse.com/range-of-products#oral, pp. 5 (downloaded Jun. 22, 2017).
[cited by applicant]
Grebe, et al., A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo- and Active-Controlled, Parallel-Group Comparison of Diclofenac-K and Ibuprofen for the Treatment of Adults with Influenza-like Symptoms, Cli…
[cited by applicant]
Haw, The HLB System, A Time Saving Guide to Surfactant Selection, Presentation to the Midwest Chapter of the Society of Cosmetic Chemists, Uniqema, URL: http://www.lotioncrafter.com/pdf/The_HLB_System.pdf, pp. 40 (2004).
[cited by applicant]
Herbarie, Emulsifiers with HLB Values, URL: http://www.theherbarie.com/files/resource-center/formulating/Emulsifiers_HLB_Values.pdf, pp. 3 (downloaded Oct. 30, 2017).
[cited by applicant]
ICI Americas, Inc., The HLB System, A Time-Saving Guide to Emulsifer Selection, pp. 22 (1980).
[cited by applicant]
Jain, et al., Development of Gelucire 43/01 Beads od Metformin Hydrochloride for Floating Delivery, AAPS Pharm. Sci. Tech. 10(4): 1128-1136 (2009).
[cited by applicant]
Juarez-Soberanez, et al., Gelucire 39/01 as Excipient Gastroretentive Metronidazole Sustained Delivery, Int. J. Pharm. Pharm. Sci. 3(2): 86-91 (2011).
[cited by applicant]
Karatas, et al., Improved Solubility and Dissolution Rate of Piroxicam Using Gelucire 44/14 and Labrasol, II Farmaco 60: 777-782 (2005).
[cited by applicant]
Khatri, Home Remedies for Ulcers, URL: http://www.steadyhealth.com/articles/homeremedies-for-ulcers, pp. 4 (downloaded Jun. 20, 2017).
[cited by applicant]
List, et al., Hydrogenation of Soybean Oil Triglycerides: Effect of Pressure on Selectivity. JAOCS 77: 311-314 (2000).
[cited by applicant]
Marchd, et al., CAS 144: 198910 (2006).
[cited by applicant]
Monzir-Pal, Characteristics of Surfactants and Emulsions, URL: http://www.monzirpal.net/Industrial/Characteristics%20of%20Surfactants%20and%20Emulsions.htm, pp. 8 (downloaded Jul. 26, 2015).
[cited by applicant]
PubChem, 1-Linoleoyl-(2S)-glycerol, URL: https://pubchem.ncbi.nlm.nih.gov/compound/6436630, pp. 20 (last modified Nov. 4, 2017).
[cited by applicant]
PubChem, 1-Monolinolein, URL: https://pubchem.ncbi.nlm.nih.gov/compound/1-Monolinolein, pp. 20 (last modified Nov. 4, 2017).
[cited by applicant]
Ren, et al., Optimization of Self Nanoemulsifying Drug Delivery System for Poorly Water-Soluble Drug using Response Surface Methodology, Drug. Dev. Ind. Pharm. 39(5): 799-806 (2013).
[cited by applicant]
Sharma, et al., Preparation and Characterization of Meloxicam-Myrj-52 Granules Obtained by Melt Granulation, PharmaTech, URL: http://www.pharmtech.com/node/230107?rel=canonical, pp. 7 (2007).
[cited by applicant]
Shen, et al., Effects of Core Tablet Size on the Functionality of Aqueous Delayed Release Coatings as Measured by SEM and LIBS, ACRYL-EZE MP, Poster Reprint (2010).
[cited by applicant]
SIGMA-ALDRICH (Millipore Sigma), Surfactants Classified by HLB Numbers, URL: https://www.sigmaaldrich.com/materials-science/material-science-products.html?T ablePage=22686648, pp. 4 (downloaded Oct. 30, 2017).
[cited by applicant]
Sinha, et al., Solid Dispersion as an Approach for Bioavailability Enhancement of Poorly Water-Soluble Drugs Ritonavir, AAPS Pharm. Sci. Tech. 11(2): 518-527 (2010).
[cited by applicant]
Strickley, Solubilizing Excipients in Oral and Inkectable Formulations, Pharma. Res. 21: 201-230 (2004).
[cited by applicant]
Vane, et al., Mechanism of Action of Anti-Inflammatory Drugs, Int. J. Tissue React. 20(1): 3-15 (1998). Abstract Only.
[cited by applicant]
Welch, Holme & Clark Co., Inc., Partially Hydrogenated Soybean Oil, (Retrieved from internet <URL:http://whc-oils.com/hydrogenated-soybean-oil_html>), pp. 2 (downloaded May 8, 2015).
[cited by applicant]
Wikipedia, Monoglyceride, URL: https://en.wikipedia.org/wiki/Monoglyceride, pp. 3 (last edited Oct. 15, 2017).
[cited by applicant]
WIPO, PCT Form ISA210, International Search Report for International Patent Application Serial No. PCT/GB2011/050189, pp. 7 (Jul. 1, 2011).
[cited by applicant]
WIPO, PCT Form ISA237, Written Opinion for International Patent Application Serial No. PCT/GB2011/050189, pp. 10 (Jul. 1, 2011).
[cited by applicant]
WIPO, PCT Form IB373, International Preliminary Report on Patentability for International Patent Application Serial No. PCT/GB2011/050189, pp. 11 (Aug. 7, 2012).
[cited by applicant]
WIPO, PCT Form ISA210, International Search Report for International Patent Application Serial No. PCT/GB2011/052115, pp. 4 (Feb. 13, 2011).
[cited by applicant]
WIPO, PCT Form ISA237, Written Opinion for International Patent Application Serial No. PCT/GB2011/052115, pp. 7 (Feb. 13, 2011).
[cited by applicant]
WIPO, PCT Form IB373, International Preliminary Report on Patentability for International Patent Application Serial No. PCT/GB2011/052115, pp. 8 (Apr. 30, 2013).
[cited by applicant]
WIPO, PCT Form ISA210, International Search Report for International Patent Application Serial No. PCT/GB2012/050241, pp. 6 (Jul. 13, 2012).
[cited by applicant]
WIPO, PCT Form ISA237, Written Opinion for International Patent Application Serial No. PCT/GB2012/050241, pp. 10 (Jul. 13, 2012).
[cited by applicant]
WIPO, PCT Form IB373, International Preliminary Report on Patentability for International Patent Application Serial No. PCT/GB2012/050241, pp. 11 (Aug. 6, 2013).
[cited by applicant]
WIPO, PCT Form ISA210, International Search Report for International Patent Application Serial No. PCT/GB2012/050242, pp. 7 (Jan. 22, 2013).
[cited by applicant]
WIPO, PCT Form ISA237, Written Opinion for International Patent Application Serial No. PCT/GB2012/050242, pp. 12 (Jan. 22, 2013).
[cited by applicant]
WIPO, PCT Form IB373, International Preliminary Report on Patentability for International Patent Application Serial No. PCT/GB2012/050242, pp. 12 (Aug. 6, 2013).
[cited by applicant]
WIPO, PCT Form ISA210, International Search Report for International Patent Application Serial No. PCT/ EP2014/050627, pp. 6 (Apr. 25, 2014).
[cited by applicant]
WIPO, PCT Form ISA237, Written Opinion for International Patent Application Serial No. PCT/EP2014/050627, pp. 7 (Apr. 25, 2014).
[cited by applicant]
WIPO, PCT Form IB373, International Preliminary Report on Patentability for International Patent Application Serial No. PCT/EP2014/050627, pp. 7 (Aug. 4, 2015).
[cited by applicant]
WIPO, PCT Form ISA210, International Search Report for International Patent Application Serial No. PCT/EP2014/050628, pp. 3 (Apr. 25, 2014).
[cited by applicant]
WIPO, PCT Form ISA237, Written Opinion for International Patent Application Serial No. PCT/EP2014/050628, pp. 5 (Apr. 25, 2014).
[cited by applicant]
WIPO, PCT Form IB373, International Preliminary Report on Patentability for International Patent Application Serial No. PCT/EP2014/050628, pp. 7 (Jul. 1, 2015).
[cited by applicant]
WIPO, PCT Form ISA210, International Search Report for International Patent Application Serial No. PCT/EP2014/050636, pp. 4 (Apr. 3, 2014).
[cited by applicant]
WIPO, PCT Form ISA237, Written Opinion for International Patent Application Serial No. PCT/EP2014/050636, pp. 6 (Apr. 3, 2014).
[cited by applicant]
WIPO, PCT Form IB373, International Preliminary Report on Patentability for International Patent Application Serial No. PCT/EP2014/050636, pp. 7 (Jul. 14, 2015).
[cited by applicant]